ArticleJournal of thoracic disease2020
CAR-T cell therapy for lung cancer: a promising but challenging future.
Article in Journal of thoracic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Non-targeted effects of stereotactic radiotherapy: a review of the evidence coming from the clinical field.Exploration of targeted anti-tumor therapy · 2025Pooled it
- Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies.Frontiers in medicine · 2026Review
- Towards the development of next-generation lung cancer immunotherapy.Translational lung cancer research · 2025Review
- Smart nanomedicines powered by artificial intelligence: a breakthrough in lung cancer diagnosis and treatment.Medical oncology (Northwood, London, England) · 2025Review
- Article
- Immune Effector Cell-Associated Neurotoxicity Syndrome After CAR T-Cell Therapy and Other Psychiatric Manifestations: A Review and Case Series.Journal of clinical medicine · 2025Review
- Clinical trials of nanoparticle-enhanced CAR-T and NK cell therapies in oncology: overcoming translational and clinical challenges - a mini review.Frontiers in medicine · 2025Review
- Adverse event profile of five anti head and neck squamous cell carcinoma drugs: a descriptive analysis from WHO-VigiAccess.Frontiers in pharmacology · 2025Article
- Adopting tomorrow's therapies today: a perspective review of adoptive cell therapy in lung cancer.Therapeutic advances in medical oncology · 2025Review
- The Role of Immunotherapy in Lung Cancer Treatment: Current Strategies, Future Directions, and Insights into Metastasis and Immune Microenvironment.Current gene therapy · 2025Review
- Plasmacytoid Dendritic Cells Mediate CpG-ODN-induced Increase in Survival in a Mouse Model of Lymphangioleiomyomatosis.American journal of respiratory cell and molecular biology · 2024Article
- PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.Cancer immunology, immunotherapy : CII · 2024Article
- Plasmacytoid dendritic cells mediate CpG-ODN induced increase in survival in a mouse model of lymphangioleiomyomatosis.bioRxiv : the preprint server for biology · 2024Article
- Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/PD-L1 blockade in the clinical spectrum of lung cancer.Molecular cancer · 2024Review
- Cutting-Edge Therapies for Lung Cancer.Cells · 2024Review
- Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors.Frontiers in immunology · 2024Review
- Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer.Current issues in molecular biology · 2023Review
- Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.Annals of translational medicine · 2023Review
- Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.Journal of translational medicine · 2023Review
- Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer.Translational lung cancer research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.